MitoStem™
T-cell quality enhancer for cell therapies
CommercialActive
Key Facts
Indication
T-cell quality enhancer for cell therapies
Phase
Commercial
Status
Active
Company
About MPC Therapeutics
MPC Therapeutics is pioneering a platform of metabolic enhancers to overcome key limitations in cell therapy, particularly CAR-T. Its core technology involves small molecules that reprogram T-cell mitochondria to boost stem cell memory populations, accelerate expansion, and improve anti-tumor efficacy. The company has transitioned to a commercial-stage entity with the launch of its first product, MitoStem™, and is backed by peer-reviewed data and industry recognition. Its business model focuses on providing these reagents as tools to cell therapy developers and manufacturers.
View full company profile